Biomimetic nanosystems harnessing NIR-II photothermal effect and hypoxia-responsive prodrug for self-amplifying and synergistic tumor treatment
Bibliographic record
Abstract
No abstract is available for this record. The assistant can identify its topic from the title, but cannot infer the study’s results.
Source: Not provided · Quality: missing
Research context
OpenAlex topics: Nanoplatforms for cancer theranostics · Cancer, Hypoxia, and Metabolism · Cancer Research and Treatments
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (55)
Show source-provided references
1. GLOBOCAN 2018: counting the toll of cancer10.1016/S0140-6736(18)32252-9 ↗
2. Drug independence and the curability of cancer by combination chemotherapy10.1016/j.trecan.2022.06.009 ↗
3. Mitochondrial-targeted and ROS-responsive nanocarrier via nose-to-brain pathway for ischemic stroke treatment10.1016/j.apsb.2023.06.011 ↗
4. Nanomedicine combats drug resistance in lung cancer10.1002/adma.202308977 ↗
5. A nanotherapeutic strategy to overcome chemotherapeutic resistance of cancer stem-like cells10.1038/s41565-020-00793-0 ↗
6. Cancer nanomedicine: progress, challenges and opportunities10.1038/nrc.2016.108 ↗
7. Tumor microenvironment-enabled nanotherapy10.1002/adhm.201701156 ↗
8. Hypoxia-active nanoparticles used in tumor theranostic10.2147/IJN.S196959 ↗
9. A hypoxia-responsive albumin-based nanosystem for deep tumor penetration and excellent therapeutic efficacy10.1002/adma.201901513 ↗
10. Sequential ultrasound-triggered and hypoxia-sensitive nanoprodrug for cascade amplification of sonochemotherapy10.1021/acsnano.1c09505 ↗
11. Tumour hypoxia causes DNA hypermethylation by reducing TET activity10.1038/nature19081 ↗
12. Targeting hypoxic tumor microenvironment in pancreatic cancer10.1186/s13045-020-01030-w ↗
13. A hypoxia-activated prodrug conjugated with a BODIPY-based photothermal agent for imaging-guided chemo-photothermal combination therapy10.1021/acsami.2c09071 ↗
14. A paclitaxel prodrug activatable by irradiation in a hypoxic microenvironment10.1002/anie.202008732 ↗
15. A self-activating nanovesicle with oxygen-depleting capability for efficient hypoxia-responsive chemo-thermo cancer therapy10.1016/j.biomaterials.2020.120533 ↗
16. In Vivo-assembled phthalocyanine/albumin supramolecular complexes combined with a hypoxia-activated prodrug for enhanced photodynamic immunotherapy of cancer10.1016/j.biomaterials.2020.120430 ↗
17. Clinical development and potential of photothermal and photodynamic therapies for cancer10.1038/s41571-020-0410-2 ↗
18. Cell death in photodynamic therapy: from oxidative stress to anti-tumor immunity10.1016/j.bbcan.2019.07.003 ↗
19. Recent advances in nanomedicines for photodynamic therapy (PDT)-driven cancer immunotherapy10.7150/thno.67300 ↗
20. Luminescent, oxygen-supplying, hemoglobin-linked conjugated polymer nanoparticles for photodynamic therapy10.1002/anie.201905884 ↗
21. Photothermal therapy10.1016/j.jconrel.2020.06.032 ↗
22. Photothermal conversion and transfer in photothermal therapy: from macroscale to nanoscale10.1016/j.cis.2022.102753 ↗
23. pH/hypoxia programmable triggered cancer photo-chemotherapy based on a semiconducting polymer dot hybridized mesoporous silica framework10.1039/C8SC02408A ↗
24. Effect of local hyperthermia on blood flow and microenvironment: a review
25. Applications of inorganic nanomaterials in photothermal therapy based on combinational cancer treatment10.2147/IJN.S239751 ↗
26. Advances in Single-component inorganic nanostructures for photoacoustic imaging guided photothermal therapy10.1016/j.addr.2022.114644 ↗
27. Organic molecule-based photothermal agents: an expanding photothermal therapy universe10.1039/C7CS00522A ↗
28. Near-infrared photodynamic and photothermal co-therapy based on organic small molecular dyes10.1186/s12951-023-02111-x ↗
29. Near-infrared-II molecular dyes for cancer imaging and surgery10.1002/adma.201900321 ↗
30. Near-infrared-II activated inorganic photothermal nanomedicines10.1016/j.biomaterials.2020.120459 ↗
31. Engineering precision nanoparticles for drug delivery10.1038/s41573-020-0090-8 ↗
32. Understanding nanoparticle toxicity mechanisms to inform redesign strategies to reduce environmental impact10.1021/acs.accounts.9b00053 ↗
33. Improving cancer immunotherapy by cell membrane-camouflaged nanoparticles10.1002/adfm.202004397 ↗
34. Cell membrane cloaked nanomedicines for bio-imaging and immunotherapy of cancer: improved pharmacokinetics, cell internalization and anticancer efficacy10.1016/j.jconrel.2021.05.018 ↗
35. In search of the 'missing self': MHC molecules and NK cell recognition10.1016/0167-5699(90)90097-S ↗
36. Immunocyte-derived nanodrugs for cancer therapy10.1002/adfm.202207181 ↗
37. Nanobiomaterials to modulate natural killer cell responses for effective cancer immunotherapy10.1016/j.tibtech.2022.06.011 ↗
38. Natural killer cells: biology and clinical use in cancer therapy
39. Natural killer cells and other innate lymphoid cells in cancer10.1038/s41577-018-0061-z ↗
40. NK cells for cancer immunotherapy10.1038/s41573-019-0052-1 ↗
41. Facilitation of molecular motion to develop turn-on photoacoustic bioprobe for detecting nitric oxide in encephalitis10.1038/s41467-021-21208-1 ↗
42. Near-infrared-II photoacoustic imaging and photo-triggered synergistic treatment of thrombosis via fibrin-specific homopolymer nanoparticles10.1038/s41467-023-42691-8 ↗
43. NIR light-driving barrier-free group rotation in nanoparticles with an 88.3% photothermal conversion efficiency for photothermal therapy10.1002/adma.201907855 ↗
44. Semiconducting polymer nanoparticles with surface-mimicking protein secondary structure as lysosome-targeting chimaeras for self-synergistic cancer immunotherapy10.1002/adma.202203309 ↗
45. Degradable controlled-release polymers and polymeric nanoparticles: mechanisms of controlling drug release10.1021/acs.chemrev.5b00346 ↗
46. Paclitaxel's mechanistic and clinical effects on breast cancer10.3390/biom9120789 ↗
47. Albumin nanoparticle containing a PI3Kγ inhibitor and paclitaxel in combination with α-PD1 induces tumor remission of breast cancer in mice10.1126/scitranslmed.abl3649 ↗
48. A photo-triggered self-accelerated nanoplatform for multifunctional image-guided combination cancer immunotherapy10.1038/s41467-023-40996-2 ↗
49. Boosting natural killer cell-mediated targeting of sarcoma through DNAM-1 and NKG2D10.3389/fimmu.2020.00040 ↗
50. Nutlin-3a enhances natural killer cell-mediated killing of neuroblastoma by restoring p53-dependent expression of ligands for NKG2D and DNAM-1 receptors10.1158/2326-6066.CIR-20-0313 ↗
51. Memory T cells expressing an NKG2D-CAR efficiently target osteosarcoma cells10.1158/1078-0432.CCR-17-0075 ↗
52. Functional expression and release of ligands for the activating immunoreceptor NKG2D in leukemia10.1182/blood-2003-01-0019 ↗
53. DNAM-1 controls NK cell activation via an ITT-like motif10.1084/jem.20150792 ↗
54. Tumor microenvironment-responsive nanoparticles amplifying STING signaling pathway for cancer immunotherapy
55. Comparison of breast cancer metastasis models reveals a possible mechanism of tumor aggressiveness10.1038/s41419-018-1094-8 ↗